Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2 | |
Ning, Meng-meng1; Yang, Wen-ji1,2; Guan, Wen-bo1,2; Gu, Yi-pei1; Feng, Ying1; Leng, Ying1,2 | |
刊名 | ACTA PHARMACOLOGICA SINICA |
2020-05-12 | |
页码 | 11 |
关键词 | ulcerative colitis dextran sulfate sodium dipeptidyl peptidase 4 sitagliptin glucagon-like peptide-2 GLP-2(3-33) apoptosis proliferation |
ISSN号 | 1671-4083 |
DOI | 10.1038/s41401-020-0413-7 |
通讯作者 | Leng, Ying(yleng@simm.ac.cn) |
英文摘要 | Dipeptidyl peptidase 4 (DPP4), a ubiquitously expressed protease that cleaves off the N-terminal dipeptide from proline and alanine on the penultimate position, has important roles in many physiological processes. In the present study, experimental colitis was induced in mice receiving 3% dextran sulfate sodium (DSS) in drinking water. We found that mice with DSS-induced colitis had significantly increased intestinal DPP activity and decreased serum DPP activity, suggesting a probable correlation of DPP4 with experimental colitis. Then, we investigated whether sitagliptin, a specific DPP4 inhibitor could protect against DSS-induced colitis. We showed that oral administration of single dose of sitagliptin (30 mg/kg) on D7 remarkably inhibited DPP enzyme activity in both serum and intestine of DSS-induced colitic mice. Repeated administration of sitagliptin (10, 30 mg/kg, bid, from D0 to D8) significantly ameliorated DSS-induced colitis, including reduction of disease activity index (DAI) and body weight loss, improvement of histological score and colon length. Sitagliptin administration dose-dependently increased plasma concentrations of active form of GLP-1 and colonic expression of GLP-2R. Co-administration of GLP-2R antagonist GLP-2(3-33) (500 mu g/kg, bid, sc) abolished the protective effects of sitagliptin in DSS-induced colitic mice. Moreover, sitagliptin administration significantly decreased the ratio of apoptotic cells and increased the ratio of proliferative cells in colon epithelium of DSS-induced colitic mice, and this effect was also blocked by GLP-2(3-33). Taken together, our results demonstrate that sitagliptin could attenuate DSS-induced experimental colitis and the effects can be attributed to the enhancement of GLP-2 action and the subsequent protective effects on intestinal barrier by inhibiting epithelial cells apoptosis and promoting their proliferation. These findings suggest sitagliptin as a novel therapeutic approach for the treatment of ulcerative colitis. |
资助项目 | National Natural Science Foundation of China[81872922] |
WOS关键词 | COLONIC EPITHELIUM ; IV ; MECHANISMS ; EXPRESSION ; MORTALITY ; SURVIVAL ; CD26 |
WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
语种 | 英语 |
出版者 | NATURE PUBLISHING GROUP |
WOS记录号 | WOS:000532186400002 |
内容类型 | 期刊论文 |
源URL | [http://119.78.100.183/handle/2S10ELR8/280292] |
专题 | 中国科学院上海药物研究所 |
通讯作者 | Leng, Ying |
作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China |
推荐引用方式 GB/T 7714 | Ning, Meng-meng,Yang, Wen-ji,Guan, Wen-bo,et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2[J]. ACTA PHARMACOLOGICA SINICA,2020:11. |
APA | Ning, Meng-meng,Yang, Wen-ji,Guan, Wen-bo,Gu, Yi-pei,Feng, Ying,&Leng, Ying.(2020).Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2.ACTA PHARMACOLOGICA SINICA,11. |
MLA | Ning, Meng-meng,et al."Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2".ACTA PHARMACOLOGICA SINICA (2020):11. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论